Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021
There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
- There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
- This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM.
- Leveraging the experience gained from the development and marketing of a treatment for Alzheimers disease, Eisai aims to establish the Eisai Dementia Platform.
- Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.